News
Public · Published
Morgan Stanley maintains Hims & Hers Health at Equal-Weight, lowers price target to $25 from $28
Morgan Stanley kept its Equal-Weight rating on Hims & Hers Health and cut its price target to $25 from $28, a 10.7% decrease. The new target implies 9.0% upside from the stock's Nov. 9 closing price of $22.94.
Published:
Updated:
What happened
Morgan Stanley kept its Equal-Weight rating on Hims & Hers Health and cut its price target to $25 from $28, a 10.7% decrease. The new target implies 9.0% upside from the stock’s Nov. 9 closing price of $22.94.
Confirmed
Global impact / market context
The lower target signals that Morgan Stanley sees less potential value for the shares than before, while retaining its Equal-Weight stance. The stated 9.0% upside is an analyst estimate, not a promised return, and may shape investor expectations rather than company revenue or costs directly.
Analyst inference
This is an analyst rating and valuation update, not a reported change in Hims & Hers Health’s business results, plans, or finances. The article gives one firm’s target and a past closing price, but no wider analyst views or market reaction.
Analyst inference
What to watch
- Whether Morgan Stanley changes its Equal-Weight rating or $25 target in a later update, which would show whether its view of the shares has shifted further. Analyst inference
- How the shares compare with the $25 target, noting that the article’s 9.0% implied upside uses the Nov. 9 close of $22.94. Analyst inference
- Any company results or business announcements that could alter the assumptions behind analyst valuation targets; none are described in this article. Analyst inference
Evidence
- Original source link unavailable